Abstract Respiratory syncytial virus (RSV) is the leading cause of infant hospitalization. All current available RSV therapeutics including antibody prophylaxis and adult vaccination target the RSV fusion glycoprotein (RSV-F).The seven neutralization sites on RSV-F are highlyconserved and infrequently mutated. Here, we show that asingle amino acid mutation at position 305 in RSV-F significantly alters antigenic recognition of RSV-F binding sites and changes the susceptibility of RSV to neutralizing antibodies. In an in vitro evolution assay, we show that RSV-F L305I occurs in the majority of RSV quasi-species. Computational modelingpredicted that the L305I mutation alters the epitope landscape of RSV-F, resulting in changes to neutralizing antibody sensitivity and affinity towards the RSV-F glycoprotein. Screening of published RSV-F sequences revealed that position 305 in RSV-F is a conserved leucine and isoleucine in RSV-A and RSV-B subtypes, respectively. Our study suggests that select amino acids in RSV-F may act asconformational switches for RSV to evade host serum antibodies. This work has important implications in understanding RSV evolution and resistance as it suggests that mutational resistance to neutralizing antibodies can also occur at sites distal to antigenic epitopes, significantly altering antibody sensitivity to viral infection. These unique antigenic landscape changes should be considered in the context of vaccine and therapeutic development in order to better understand viral mechanisms of evasion and resistance.
No takes yet. Share an insight, caveat, or question.
Oraby et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: